Abstract | BACKGROUND: METHODS: The study cohort included 176 patients (at least >12 months follow-up) with HBV cirrhosis/ hepatocellular carcinoma who received secondary prophylaxis with indefinite entecavir/ tenofovir after living-donor LT (LDLT). All patients received 10,000 IU intravenous HBIG in anhepatic phase followed by 600-1000 IU intramuscularly daily for 7 days, weekly for 3 weeks, and then monthly, to keep antiHBs levels >100 mIU/mL for 1 year. Hepatitis B surface antigen ( HBsAg) and HBV DNA were tested every 6 months. RESULTS: The study cohort is composed of 157 men and 19 women, mean age 47.9 ± 10.1 years, all HBsAg positive, 35 (19.8%) had HBV DNA >2000 IU/mL before LT. After LT, patients received entecavir (n = 126, 71.5%), tenofovir (n = 20, 11.3%), or a combination of entecavir and tenofovir ( n = 30, 17% for 3 months), followed by entecavir alone. During follow-up of 43 (12-117) months, 2 patients (including 1 with non-compliance) had HBV recurrence. CONCLUSION: In a large cohort of LDLT recipients for HBV-related liver disease, use of low-dose short-term HBIG with high genetic barrier drugs results in a substantially lower incidence of HBV recurrence, even in high-risk patients.
|
Authors | N S Choudhary, N Saraf, S Saigal, R Mohanka, A Rastogi, S Goja, P B Menon, A S Soin |
Journal | Transplant infectious disease : an official journal of the Transplantation Society
(Transpl Infect Dis)
Vol. 17
Issue 3
Pg. 329-33
(Jun 2015)
ISSN: 1399-3062 [Electronic] Denmark |
PMID | 25682715
(Publication Type: Journal Article)
|
Copyright | © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. |
Chemical References |
- Antiviral Agents
- Hepatitis B Surface Antigens
- Immunoglobulins
- Organophosphonates
- Lamivudine
- entecavir
- Guanine
- adefovir
- Tenofovir
- Adenine
- hepatitis B hyperimmune globulin
|
Topics |
- Adenine
(administration & dosage, analogs & derivatives)
- Adult
- Antiviral Agents
(administration & dosage)
- Carcinoma, Hepatocellular
(prevention & control, virology)
- Cohort Studies
- Drug Resistance, Viral
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Guanine
(administration & dosage, analogs & derivatives)
- Hepatitis B
(prevention & control, virology)
- Hepatitis B Surface Antigens
(immunology)
- Hepatitis B virus
(genetics, immunology)
- Humans
- Immunoglobulins
(administration & dosage)
- Lamivudine
(administration & dosage)
- Liver Transplantation
(adverse effects)
- Male
- Middle Aged
- Organophosphonates
(administration & dosage)
- Prospective Studies
- Recurrence
- Tenofovir
(administration & dosage)
|